First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233004, China.
School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.
BMC Public Health. 2024 Oct 21;24(1):2888. doi: 10.1186/s12889-024-20330-1.
Reliable estimates of asthma prevalence are essential for developing effective public health policies. However, discrepancies in published results have posed challenges for public health planning in China. To address this issue, we conducted this study to provide a comprehensive assessment of the epidemiology of asthma prevalence in China.
We conducted a thorough systematic review across multiple databases including PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Weipu database. The search was limited to studies published in either Chinese or English up to August 31, 2023, that reported on asthma prevalence in China. We extracted relevant study characteristics and performed meta-analyses. The study protocol was registered with PROSPERO (CRD42023397949).
A literature search yielded 192 studies that met the inclusion criteria out of 17,152 articles. The overall prevalence of asthma in Mainland China was found to be 2.20% (95% confidence interval, CI: 1.96-2.47%; I = 99.8%), with the prevalence of ever asthma at 2.21%, current asthma at 2.16%, ever asthma-like symptoms at 14.36%, and current asthma-like symptoms at 3.01%. Using a random-effects model, the prediction interval ranged from 0.44 to 10.27%. Meta-analysis subgroups indicated that men or children and the elderly generally have a higher prevalence of asthma. In addition, the prevalence of asthma is higher in urban areas and in the East China. The prevalence of asthma has been on the rise over the past three decades, from 0.69% in 1984 to 5.30% in 2021. Projections suggest that the prevalence could reach 9.76% by 2050 for the Chinese population.
Asthma remains less prevalent in China than in western countries, however its prevalence has been gradually increasing over the past thirty years. The disease burden shows notable variations based on sex, age, and geographic regions, indicating significant demographic and regional disparities. To guide decision-making priorities and direct future research, conducting high-quality epidemiological studies on asthma is crucial.
可靠的哮喘患病率估计对于制定有效的公共卫生政策至关重要。然而,发表的结果存在差异,这给中国的公共卫生规划带来了挑战。为了解决这个问题,我们进行了这项研究,以提供中国哮喘患病率的综合评估。
我们在多个数据库中进行了全面的系统综述,包括 PubMed、Embase、Web of Science、中国国家知识基础设施(CNKI)、万方数据和维普数据库。搜索范围限于截至 2023 年 8 月 31 日,以中文或英文发表的报告中国哮喘患病率的研究。我们提取了相关的研究特征并进行了荟萃分析。该研究方案已在 PROSPERO(CRD42023397949)上注册。
从 17152 篇文章中检索到 192 篇符合纳入标准的研究。中国大陆的哮喘总体患病率为 2.20%(95%置信区间,CI:1.96-2.47%;I=99.8%),其中既往哮喘患病率为 2.21%,现患哮喘患病率为 2.16%,既往哮喘样症状患病率为 14.36%,现患哮喘样症状患病率为 3.01%。使用随机效应模型,预测区间范围为 0.44 至 10.27%。亚组分析表明,男性或儿童和老年人的哮喘患病率通常较高。此外,城市和华东地区的哮喘患病率较高。在过去的三十年中,哮喘的患病率一直在上升,从 1984 年的 0.69%上升到 2021 年的 5.30%。预测表明,到 2050 年,中国人口的哮喘患病率可能达到 9.76%。
与西方国家相比,中国的哮喘患病率较低,但在过去三十年中呈逐渐上升趋势。疾病负担因性别、年龄和地理区域而异,表明存在显著的人口和地区差异。为了指导决策优先事项并指导未来的研究,开展高质量的哮喘流行病学研究至关重要。